Linopristin/flopristin

Linopristin/Flopristin is a combination of two antibiotics, linopristin and flopristin, used in the treatment of infections caused by Gram-positive bacteria. It is marketed under the brand name Synercid.

Mechanism of Action

The combination of linopristin and flopristin works by inhibiting the protein synthesis of bacteria. Linopristin binds to the 50S subunit of the bacterial ribosome, preventing the formation of a functional 70S initiation complex. Flopristin binds at a nearby site, causing a conformational change that enhances the binding of linopristin. This dual action results in a synergistic bactericidal effect.

Indications

Linopristin/flopristin is indicated for the treatment of serious or life-threatening infections caused by vancomycin-resistant Enterococcus faecium (VREF) bacteremia. It is also used for skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains) or Streptococcus pyogenes.

Side Effects

Common side effects of linopristin/flopristin include nausea, vomiting, diarrhea, rash, and pain or inflammation at the injection site. Serious side effects may include allergic reactions, thrombophlebitis, and superinfection.

Contraindications

Linopristin/flopristin is contraindicated in patients with known hypersensitivity to either linopristin or flopristin or any component of the formulation.

Drug Interactions

Linopristin/flopristin may interact with other drugs, including warfarin, cyclosporine, and digoxin. Therefore, caution should be exercised when co-administering these drugs.

Dosage and Administration

The recommended dosage of linopristin/flopristin is 7.5 mg/kg every 8 hours, administered by intravenous infusion over 60 minutes.

See Also

• Antibiotics
• Protein synthesis inhibitors
• Vancomycin-resistant Enterococcus

Linopristin/flopristin Resources
Latest articles Most recent articles Ongoing trials	Wikipedia